This portfolio primarily directs its capital, dedicating a minimum of 80% of its total assets, towards equity holdings—chiefly common shares—of companies operating within the health sciences and closely related sectors. This comprehensive category includes businesses involved in medical equipment and supplies, healthcare service provision, biotechnology, and pharmaceutical research and manufacturing. The fund maintains a focused investment approach, ensuring that more than a quarter (over 25%) of its assets are committed to these health sciences industries. Additionally, it has the flexibility to include investments in companies based outside of the United States.
Sector exposure data isn't available for this fund yet.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| — | UNITEDHEALTH GROUP INC | 9.31% | $787.09M |
| — | ELI LILLY | 8.48% | $716.80M |
| — | BOSTON SCIENTIFIC CORP | 5.35% | $452.15M |
| — | AMGEN INC | 4.06% | $342.80M |
| — | THERMO FISHER SCIENTIFIC INC | 3.75% | $317.26M |
| — | DANAHER CORP | 3.56% | $301.10M |
| — | ABBVIE INC | 3.27% | $276.38M |
| — | BLACKROCK LIQ FUND T-FD-IN | 3.26% | $275.15M |
| — | INTUITIVE SURGICAL INC | 3.19% | $270.01M |
| — | ELEVANCE HEALTH INC | 2.95% | $249.58M |
| — | MERCK & CO INC | 2.66% | $224.75M |
| — | STRYKER CORP | 2.60% | $220.13M |
| — | MCKESSON CORP | 2.53% | $213.89M |
| — | CENCORA INC | 2.49% | $210.39M |
| — | VERTEX PHARMACEUTICALS INC | 2.16% | $182.94M |
| — | JOHNSON & JOHNSON | 2.14% | $180.65M |
| — | ABBOTT LABORATORIES | 2.08% | $175.64M |
| — | CIGNA | 1.82% | $153.71M |
| — | REGENERON PHARMACEUTICALS INC | 1.69% | $142.95M |
| — | PFIZER INC | 1.59% | $134.48M |
| — | BIOGEN INC | 1.47% | $123.98M |
| — | ALNYLAM PHARMACEUTICALS INC | 1.38% | $116.54M |
| — | ARGENX SE ADR | 1.35% | $114.29M |
| — | BECTON DICKINSON | 1.31% | $111.04M |
| — | HCA HEALTHCARE INC | 1.12% | $94.70M |
